HALOHalozyme Therapeutics, Inc.
Price
+42%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Halozyme Therapeutics, Inc. (HALO) reported revenue of $481M in Q2 2026 (quarter ended Jun 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 84% and net income of $230M (48% of revenue). For the full year FY2025, revenue was $1.40B (+38% year on year) and net income $317M. Its largest product in Q2 2026 was Royalty at $308M, 59% of the disclosed total, well ahead of Bulk R Hu PH20 at 11%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2029 and was not initially assigned to any Board committee.Director or officer change · Form 8-K
- Sep 22, 2026Convertible Notes Indentures On September 22, 2026, Halozyme Therapeutics, Inc. (the “Company,” “we,” “us” or “our”) completed its previously announced sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033 (the “Convertible Notes”), including $200.0 million in aggregate …Material agreement entered · Form 8-K
- Sep 18, 2026On September 17, 2026, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $1.3 billion aggregate principal amount of convertible senior notes due 2033 (the “Convertible Notes”)Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $524.7MThe company’s own SEC segment disclosure.
- Royalty$307.7M59%
- Bulk R Hu PH20$59.6M11%
- Proprietary Products Sales$55.4M11%
- Collaborative Agreements$43.7M8%
- Upfront Fees$35.5M7%
- Device Partnered Products$14.6M3%
- Other (2)$8.2M2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.